Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells

Thyroid cancer is the most common endocrine malignancy. A multitargeted tyrosine kinase inhibitor, lenvatinib, has been used for the treatment of advanced thyroid cancer. To elucidate the mechanism of resistance to lenvatinib in thyroid cancer cells, we established lenvatinib‐resistant sublines and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohno, Koichi, Shibata, Tomohiro, Ito, Ken‐ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459297/
https://www.ncbi.nlm.nih.gov/pubmed/35723021
http://dx.doi.org/10.1111/cas.15465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459297/
https://www.ncbi.nlm.nih.gov/pubmed/35723021
http://dx.doi.org/10.1111/cas.15465

Ejemplares similares